

genedrive plc
("genedrive" or the "Company")

Result of AGM

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.

For information, details of the proxy voting are shown below:

Resolution	Votes For	Votes For (as % of votes cast)	Votes Against	Votes Against (as % of votes cast)	Votes Withheld
1. Receive the Annual report and accounts for the Company	22,673,789	100.0%	0	0.00%	515
2. Approve the Directors' Remuneration Report	21,886,545	96.5%	787,131	3.47%	628
3. Re-appoint Tom Lindsay as a director	22,674,304	100.0%	0	0.00%	0
4. Re-appoint Chris Yates as a director	22,674,304	100.0%	0	0.00%	0
5. Re-appoint David Budd as a director	22,674,304	100.0%	0	0.00%	0
6. Re-appoint Matthew Fowler as a director	22,674,304	100.0%	0	0.00%	0
7. Re-appoint Ian Gilham as a director	21,887,370	100.0%	314	0.00%	786,620
8. Appoint RSM UK as auditors of the Company	22,674,304	100.0%	0	0.00%	0
9. Directors' authority to allot shares	22,109,087	100.0%	0	0.00%	565,217
10. Disapplication of pre-emption rights	19,551,681	88.4%	2,556,891	11.57%	565,732

The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.genedriveplc.com).

- Ends -

For further details please contact:

genedrive plc

David Budd: CEO / Matthew Fowler: CFO

www.genedriveplc.com

+44 (0)161 989 0245

Peel Hunt LLP

James Steel / Oliver Jackson

+44 (0)20 7418 8900

Stanford Capital Partners Limited

Patrick Claridge / John Howes

+44 (0)20 3815 8880

Walbrook PR Ltd (Media Relations & Investor Relations)

Paul McManus / Anna Dunphy

+44 (0)20 7933 8780

or genedrive@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7876 741

001

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® mt-RNR1-ID kit has received CE-IVD Certification and will be launched into Europe and other markets following full evaluation by the UK National Health Service. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lse.com or visit www.rns.com.

END

RAGBLBDBGDDBGCR